319
Participants
Start Date
April 13, 2021
Primary Completion Date
June 15, 2022
Study Completion Date
June 15, 2022
Ruxolitinib
As per treating physician's decision - non interventional study
Extracorporeal photopheresis
As per treating physician's decision - non interventional study
Ibrutinib
As per treating physician's decision - non interventional study
Antwerp University, Antwerp
University of Liège, Liège
Rigshospitalet, Copenhagen
CHRU Angers, Angers
CHU de Limoges, Limoges
Institut de Cancerologie Lucien Neuwirth, Saint-Etienne
Bonn University, Bonn
University Hospital Essen, Essen
Universitaetsmedizin Mannheim, Mannheim
Robert_Bosch_Krankenhaus, Stuttgart
George Papanicolaou General Hospital, Thessaloniki
Rambam Medical Center, Haifa
H SS. Antonio e Biagio, Alessandria
ASST Papa Giovanni XXIII, Bergamo
Istituto Clinico Humanitas, Milan
Ospedale Civile, Pescara
Azienda Ospedaliero Universitaria Pisana, Pisa
Universita Cattolica S. Cuore, Roma
S. Bortolo Hospital, Vicenza
Medical University of Gdansk, Gdansk
Fundeni Clinical Institute, Bucharest
First State Pavlov Medical University of St. Petersburg, Saint Petersburg
ICO-Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Clinic, Barcelona
ICO - Hospital Duran i Reynals, Barcelona
Hosp. Reina Sofia, Córdoba
Hospital Univ. Virgen de las Nieves, Granada
Hospital Regional de Málaga, Málaga
Hospital Universitario Virgen del Rocío, Seville
Sahlgrenska University Hospital, Gothenburg
Skanes University Hospital, Lund
Baskent University Hospital, Adana
Gazi University Faculty of Medicine, Ankara
University Hospital Birmingham NHS Trust, Birmingham
Bristol Royal Hospital for Children, Bristol
Kings College Hospital, London
Christie NHS Trust Hospital, Manchester
Churchill Hospital, Oxford
Collaborators (1)
Mallinckrodt
INDUSTRY
European Society for Blood and Marrow Transplantation
NETWORK